


MAIA is an immuno-oncology company focused on the development and commercialization of first-in-class drugs intended to meaningfully improve and extend the lives of people with hard-to-treat cancers. We are exploring new science for cancer therapy utilizing a novel dual mechanism of action: telomere targeting and immunogenicity. Our lead program is ateganosine (THIO), a first-in-class anticancer agent in clinical development for the treatment of Non-Small Cell Lung Cancer (NSCLC) in patients.



Company Highlights

Clinical Programs

THIO-101

Ph 2 trial of THIO + Libtayo® (cemiplimab)

- Data in NSCLC third-line indicates that efficacy as of May 2025:
 - Estimated Median Overall Survival (OS) is at 17.8 months
 - 12.5 months (95% lower confidence limit);
 - 10.8 months (99% lower confidence limit);
- Expansion to start enrolling in H1 2025
- Potential filing for accelerated approval in 2026

THIO-104 (planning)

Ph 3 trial of ateganosine (THIO) + checkpoint inhibitors

- Full approval trial planned to start in 2025
- Focus on execution: probability of OS to be > 7.8 months (HR 0.74 vs. chemo) is >99%
- Interim analysis can lead to potential filing for early full commercial approval in 2026

THIO-102 (planning)

Ph 2 trials of ateganosine (THIO) + checkpoint inhibitor

- Three planned trials in late lines of therapy in multiple tumor types: Colorectal Cancer (CRC), Hepatocellular Carcinoma (HCC, 90% of primary type of liver cancers), Small Cell Lung Cancer (SCLC)
- Potential to file for accelerated approvals in 2027 and beyond

THIO-103 (planning)

Ph 2/3 trial of THIO + checkpoint inhibitors

- First-line NSCLC and SCLC
- Expand to other indications
- Objectives: confirmatory for accelerated approvals from previous THIO trials

Ateganosine (THIO) is a Unique Direct Telomere Targeting Agent

- Potential to be used in combination with other anticancer and immune therapies
- Novel dual mechanism of action: telomere targeting + immunogenic
- 3 FDA Orphan Drug Designations: HCC, SCLC, and Glioblastoma and 1 Rare Pediatric Disease Designation for pediatric-type diffuse high-grade gliomas
- Excellent efficacy: achieved complete and durable responses in HCC *in vivo* models (peer-reviewed published study)
- Featured in multiple renowned scientific publications including Cancer Cell and Nature



Partnerships and Collaborations

- THIO-101: clinical supply agreement with Regeneron, provides Libtayo® for all patients in the trial
- Clinical supply agreement with BeOne Medicines for trials in CRC, HCC and SCLC
- Broad potential for partnerships with different companies and checkpoint inhibitors in upcoming clinical trials

Cap Table

NYSE American: MAIA

Share Price ¹	\$2.04	Float ²⁻³	25.1M
Market Cap ¹	\$60.4M	Insider Holdings ²	15%
FD Shares Outstanding ²	49.8M	Cash ²	\$10.9M

1. As of May 9, 2025

2. As of March 31, 2025

3. Defined as: (total common shares) – (common shares held by Directors & Officers)

MAIA Biotechnology's goal is to bring revolutionary cancer treatments to the market, with the only direct telomere targeting agent in clinical development. MAIA is developing agents for the top tumor types markets globally.



Significant Market Opportunity

- Cancer is the most dominant of the age-related disease categories and has life altering impacts in the lives of patients and their close ones
- The number of people aged 80 years or older is expected to triple between 2021 and 2050 to reach 459 million
- Approximately 40% of people alive today are projected to be diagnosed with a cancer type in their lifetime, and 20% will die of it
- NSCLC is the leading tumor type: Mortality 1.7M / Sales \$34B (2023)
- CRC is second: Mortality 1M / Sales \$20B (2023)



Strong and Growing IP Portfolio

- Potential for receiving NCE marketing exclusivity
- 9 patents issued, 22 patent applications pending

Next Generation Potential Telomere Targeting Therapeutics in R&D

- 84 new molecules engineered; same mechanism of action as THIO
- Following ateganosine (THIO) to commercial stage within 4-5 years

Robust Pipeline

Ateganosine (THIO) Telomere Targeting Agent

Clinical Trial	Indication	Treatment	Status	Preclinical	Phase 1	Phase 2	Phase 3	Rights
THIO-104	NSCLC 3L	Ateganosine → Libtayo®	Initiating Phase 3					Worldwide rights owned by MAIA
THIO-101	NSCLC 2L+	Ateganosine → Libtayo®	Ongoing Phase 2			Clinical supply agreement with REGENERON		
THIO-102-CRC	CRC 3L+	Ateganosine → tislelizumab	Planned Phase 2			Clinical supply agreement with BeOne		
THIO-102-HCC	HCC 2L+	Ateganosine → tislelizumab	Planned Phase 2			Clinical supply agreement with BeOne		
THIO-102-SCLC	SCLC 2L+	Ateganosine → tislelizumab	Planned Phase 2			Clinical supply agreement with BeOne		
THIO-103	NSCLC 1L, SCLC 1L	Ateganosine → tislelizumab	Planned Phase 2/3					

2nd Generation Telomere Targeting Agents

Agent	Indication	Status	Preclinical	Phase 1	Phase 2	Phase 3	Rights
MAIA-2021-020	Multiple Tumor Types	IND Enabling					Developed in-house fully-owned by MAIA
MAIA-2022-012	Multiple Tumor Types	IND Enabling					
MAIA-2021-029	Multiple Tumor Types	IND Enabling					



Vlad Vitoc, MD, MBA

Founder, Chairman, and Chief Executive Officer

- 25+ years in Pharma/Biotech: Commercial, Medical,
- 12 compounds launched across 20+ tumor types
- Leadership roles at Bayer (Nexavar), Astellas (Tarceva, Xtandi), Cephalon (Treanda), Novartis (Zometa), and Incyte (Jakafi)

DISCLAIMER: This information is published solely for informational purposes and is not to be construed as a solicitation or an offer to buy any security or related financial instrument or to participate in any trading strategy. The summary may include "forward-looking statements" with the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Exchange Act of 1934 and are intended to be covered by the safe harbor provisions for forward looking statements. This information is supplied from sources we believe to be reliable but we cannot guarantee accuracy. This document is furnished to you solely for your information.



Scan QR Code to
access our
investor
presentation